ACAD logo

ACAD Acadia Pharmaceuticals Inc.

NASDAQ Global Select · Biotechnology · Healthcare

$17.59
-0.24 (-1.35%)

Acadia Pharmaceuticals Inc. operates as a biopharmaceutical company, primarily dedicated to discovering, developing, and commercializing small molecule therapeutics. Their core focus lies in addressing critical unmet medical needs within the realm of central nervous system (CNS) disorders. The company's marketed product, NUPLAZID (pimavanserin), is prescribed for the management of hallucinations a…

Market Cap: $3.04Bwww.acadia.com

Price

No data yet.

Social Signal Score

50
5d
—
30d
53
6 mentions
—
60d
49
17 mentions
—
90d
48
21 mentions
—
marketaux: 2 · rss: 4 · news: 15

Analyst Ratings

37 analysts
Buyconsensus
Strong Buy 0Buy 25Hold 11Sell 1Strong Sell 0
Avg price target$29.68+68.7%
Low $14.5Median $33High $38
Current Consensus

Revenue

$342.29M+2761.49%
$11.96M$122.07M$232.18M$342.29M
Dec 2016Sep 2026

Analyst Estimates

FY2025
$0.81
$0.72–$0.89
13 analysts
FY2026
$0.77-5% YoY
$0.57–$1.05
12 analysts
FY2027
$1.05+37% YoY
$0.49–$1.82
13 analysts

Consensus estimates, not results. Via Financial Modeling Prep.

Company Profile

CEO
Catherine E. Owen Adams
Sector
Healthcare
Industry
Biotechnology
Employees
797
Beta
0.89
Country
US
Piotroski score
4 / 9 (Middling)
Altman Z-score
4.75
www.acadia.com